Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In
recent years, transarterial chemoembolization, radio frequency ablation and microwave
ablation have been accepted as treatment modalities for patients with surgically unresectable
hepatocellular carcinoma.